Search

Your search keyword '"Sothi, Sharmila"' showing total 41 results

Search Constraints

Start Over You searched for: Author "Sothi, Sharmila" Remove constraint Author: "Sothi, Sharmila"
41 results on '"Sothi, Sharmila"'

Search Results

1. Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial

2. Multi-Omic Analysis of Esophageal Adenocarcinoma Uncovers Candidate Therapeutic Targets and Cancer-Selective Posttranscriptional Regulation

3. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial

4. NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

5. Serial ctDNA detection using a personalized, tumor-informed assay in esophageal adenocarcinoma patients following resection

6. Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial

7. Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts

8. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial

9. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

10. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS):an open-label, randomised, phase 3 trial

11. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

12. Combined burden and functional impact tests for cancer driver discovery using DriverPower

13. Integrative pathway enrichment analysis of multivariate omics data

14. Pathway and network analysis of more than 2500 whole cancer genomes

15. Divergent mutational processes distinguish hypoxic and normoxic tumours

16. Genomic footprints of activated telomere maintenance mechanisms in cancer

17. Health-related quality of life (HRQoL) in patients (pts) with progressive, poorly differentiated, extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) enrolled in NET-02: A phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy

18. Serial circulating tumor DNA detection using a personalized, tumor-informed assay in esophageal adenocarcinoma patients following resection

19. Pan-cancer analysis of whole genomes

20. Identification of Subtypes of Barrett’s Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data

21. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial

22. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma : A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial

23. Multi-Omic Analysis of Esophageal Adenocarcinoma Uncovers Candidate Therapeutic Targets and Cancer-Selective Posttranscriptional Regulation

24. Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial

25. Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma

26. Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts

27. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4) : a multicentre, open-label, randomised, phase 3 trial

28. Screening for malnutrition in patients with gastro-entero-pancreatic neuroendocrine tumours: a cross-sectional study

30. Cancer nanotechnology.

31. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

32. Sex differences in oncogenic mutational processes

33. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

34. NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC)

35. Pan-cancer analysis of whole genomes

36. Sex differences in oncogenic mutational processes

37. Patient-specific cancer genes contribute to recurrently perturbed pathways and establish therapeutic vulnerabilities in esophageal adenocarcinoma

38. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

39. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

40. NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC)

41. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.

Catalog

Books, media, physical & digital resources